Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Calcium gluconate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Calcium Gluconate 10 % w/v Injection BP is a solution for the supplementation of calcium. It is used for the supply of calcium in patients with abnormally low blood calcium levels (hypocalcaemia) and presenting with acute symptoms such as impaired skin sensations (numbness, itching, burning), convulsive muscular rigidity (tetany), cramps in the hands and feet, colic, muscle weakness, confusion, possibly culminating in convulsions and cardiac symptoms (e.g. irregular heartbeat and even acute heart failure). It is also used: ● to prevent abnormal heartbeat (arrhythmia) due to high potassium levels in the blood (severe hyperkalaemia) ● to help restore normal heart function in an emergency (cardiac arrest) if potassium levels in the blood are too high 2.
e Calcium Gluconate 10 % w/v Injection BP
Do not use Calcium Gluconate 10 % w/v Injection BP ● if you are allergic to calcium gluconate or any of the other ingredients of this medicine (listed in section 6) ● if you have elevated blood calcium levels (e.g. in patients with overactive parathyroid glands, elevated vitamin D levels in the blood, tumour diseases with bone decomposition, impaired kidney function, osteoporosis due to a lack of mobility, sarcoidosis and so-called milk-alkali syndrome) ● in the case of excessive excretion of calcium in the urine ● in the case of poisoning with digitalis medicines (a kind of heart medicine) ● during treatment with digitalis medicines unless you have an extremely low blood calcium level with life-threatening symptoms, which can only be treated by an immediate injection of calcium.
●
the antibiotic ceftriaxone should not be used in premature neonates and neonates (≤ 28 days of age) if they are receiving (or are expected to receive) calcium-containing products which are administered into a vein.
Warnings and precautions Talk to your doctor before using Calcium Gluconate 10 % w/v Injection BP. If you are taking digitalis preparations on a regular basis and, as an exception, you urgently require a calcium injection (see above), your doctor will monitor your heart function extremely carefully. The monitoring will ensure, that any worsening of your heart function, e.g. severe arrhythmias (irregular heartbeat), can be treated immediately. Your doctor will consider very carefully whether this medicine is suitable for you if you suffer from: ● deposition of calcium in the kidneys (nephrocalcinosis) ● heart diseases ● sarcoidosis, In these cases you should only be given calcium injections if these are absolutely essential. This also applies if you receive adrenaline (see "Other medicines and Calcium Gluconate 10 % w/v Injection BP") or are elderly. Impaired kidney function (kidney impairment) can be accompanied by increased blood calcium levels and overactive parathyroid glands. If you are suffering from kidney impairment, you should only receive calcium injections if these are absolutely essential. Your calcium and phosphate balance must, however, be monitored. Your doctor will take special care if you are receiving the antibiotic ceftriaxone. He will not administer it to you simultaneously with calcium gluconate even via different infusion line or different infusion sites. Calcium should be injected slowly in order to prevent, where possible, widening of the blood vessels or impaired cardiac function. Your heart rate or EEG should be monitored when this medicine is injected into a vein (intravenous injection). During calcium salt treatment, you will be carefully monitored to ensure a normal calcium balance (calcium intake versus calcium excretion) and to prevent any chalky deposits in the tissue. Blood calcium levels and the quantities of calcium excreted in the urine will be monitored especially when calcium is injected at high doses. Calcium is insoluble in fatty tissue and may lead to inflammatory reactions followed by abscess formation, hardening of the tissue and tissue destruction (necrosis) if accidentally injected into these areas. If the solution is inadvertently injected beside a blood vessel or not deep enough into a muscle, this can result in local tissue irritation, possibly followed by peeling of the skin or even necrosis (see section 4). Your doctor will ensure that no solution drains into tissue around the blood vessel and will carefully observe the site of injection. High doses of vitamin D should be avoided. Children and adolescents In children (< 18 years) Calcium Gluconate 10 % w/v Injection BP should only be injected into veins, not into a muscle (intramuscular).
Other medicines and Calcium Gluconate 10 % w/v Injection BP Tell your doctor if you are taking or have recently taken any other medicines. The effect of heart medicines like digoxin and other digitalis medicines can be increased by calcium up to the point of digitalis poisoning. Therefore, if you are receiving treatment with digitalis medicines, you will only be given an intravenous calcium injection for the treatment of severe, immediately life-threatening symptoms of a very low blood calcium level. Administration of calcium together with adrenaline after heart surgery weakens the effects of adrenaline on the heart and circulation. Calcium and magnesium mutually inhibit their effects. Calcium can reduce the effects of certain medicines used to regulate heart function (calcium antagonists). Administration of certain medicines increasing the urine formation and output (thiazide diuretics) together with calcium can lead to excessively high blood calcium levels (hypercalcaemia), as these medicinal products reduce the excretion of calcium via the kidneys. Administration of calcium simultaneously with ceftriaxone will lead to agglomeration. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you maybe pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Pregnancy Calcium passes through the placenta into the circulation of the foetus and reaches higher levels in the foetal blood than in the mother's blood. Pregnant women should, therefore, only receive calcium injections if absolutely essential. The dose must then be carefully calculated and calcium levels in the blood regularly monitored in order to avoid excessive calcium levels in the blood, which could be harmful to the foetus. Breast-feeding Calcium is excreted into breast milk. Your doctor will keep this in mind when administering calcium to you when you are breast-feeding your infant. Driving and using machines This medicine has no influence on the ability to drive and use machines.
3.
Calcium Gluconate 10 % w/v Injection BP
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The recommended dose will selected by your doctor in order to raise your blood calcium level / your child's blood calcium level to normal values. Replacement of low levels of calcium in the body (acute symptomatic hypocalcaemia) Adults
The usual starting dose is 10 ml, i.e. one ampoule of Calcium Gluconate 10 % w/v Injection BP. If required, the dose may be repeated. Following doses will be adjusted according to your actual blood calcium level. Use in infants, toddlers, children and adolescents The doctor will decide on the dosage and method of administration depending on the blood calcium level and the severity of the symptoms. In the case of mild symptoms affecting the nerves and muscles, preference will be given to oral calcium preparations. The following table gives usual initial dosage values for guidance: Age 3 months 6 months 1 year 3 years 7.5 years 12 years > 12 years
ml/kg 0.4 – 0.9 0.3 – 0.7 0.2 – 0.5 0.4 – 0.7 0.2 – 0.4 0.1 – 0.3 as for adults
In the case of exceptionally low blood calcium levels in neonates and infants with, for instance, impaired cardiac function, higher starting doses may be required in order to quickly raise the blood calcium levels (up to 2 ml per kg body weight). Calcium administration can be repeated, if required. The concentration of the following doses will depend on the existing blood calcium level. Following intravenous therapy treatment with oral calcium preparations may be necessary, e.g. in cases of vitamin D deficiency. Prevention of abnormal heartbeat (arrhythmia) due to high potassium levels in the blood (severe hyperkalaemia) and for cardiac arrest due to too high potassium levels in the blood Calcium therapy for severe hyperkalaemia (serum potassium concentration above 6.5 mmol/L in adults) is an emergency treatment aiming to reduce cardiac cell excitability (cardioprotective effect) while other measures to lower potassium levels are instituted. For cardiac arrest Calcium Gluconate 10% solution for injection/infusion should be given only if caused by severe hyperkalaemia. Elderly patients Certain disorders that are sometimes associated with advanced age, such as impaired kidney function and undernourishment (malnutrition) may affect the tolerance of calcium gluconate. Therefore, a lower dose must be selected. Method of administration Calcium Gluconate 10 % w/v Injection BP will be given to you as an injection slowly into a vein or deep into a large muscle. It should be given to you in a lying position and in particular your heart function should be carefully monitored during the injection. Due to the risk of local tissue irritation, injections into a muscle (intramuscular injection) should only be made if intravenous injection is not feasible. Your doctor will carefully ensure that the intramuscular injections are administered sufficiently deep, preferably into the large buttock muscle. The rate of intravenous infusion or injection should be sufficiently slow. Infants, toddlers, children and adolescents
For intravenous (into a vein) administration as a slow injection or slow intravenous infusion (venous drip), both after dilution. In children, this medicine should not be injected into a muscle or under the skin. If you receive more Calcium Gluconate 10 % w/v Injection BP than you should Symptoms of a high blood calcium level (hypercalcaemia) include: loss of appetite, feeling sick, being sick (vomiting), constipation, belly ache, passing large quantities of urine, increased thirst, fluid loss, muscle weakness, deposition of calcium in the kidneys, drowsiness, confusion, high blood pressure (hypertension) and, in severe cases, irregular heartbeat, up to the point of cardiac arrest and loss of consciousness. Symptoms of high blood calcium level (hypercalcaemia) and chalky taste, hot flushes and a drop in blood pressure can occur if the intravenous injection is made too rapidly. Treatment is aimed at lowering the elevated high blood calcium levels. Your doctor will decide on the treatment to be given. It may include administration of fluids or specific medication to lower the blood calcium level. In severe cases dialysis may become necessary. If you have any further questions on the use of this medicine, ask your doctor.
4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The frequency of side effects is expressed as follows: Very common: affects more than 1 user in 10 Common: affects 1 to 10 users in 100 Uncommon: affects 1 to 10 users in 1,000 Rare: affects 1 to 10 users in 10,000 Very rare: affects less than 1 user in 10,000 Not known: frequency cannot be estimated based on the available data. Side effects on the heart, circulation or other body functions may appear as symptoms of an excessively high blood calcium level after overdosing or too rapid injection into a vein. The presence and frequency of such symptoms depend directly on the speed of injection and the dose administered. The following side effects may be serious. If any of the following side effects occur tell your doctor immediately, he will stop giving you this medicine: Not known (Frequency cannot be estimated from the available data): ● slow or irregular heartbeat ● drop in blood pressure (hypotension) ● circulatory collapse (possibly fatal) Rarely (affects 1 to 10 users in 10, 000): Severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged <28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. Other side effects include:
Not known (Frequency cannot be estimated from the available data): ● widening of blood vessels, ● hot flushes, mainly after the injection has been administered too rapidly. ● feeling sick or being sick (vomiting) ● sensation of heat ● sweating ● injections into muscles may be accompanied by pain and redness
when the medicinal product is used incorrectly ● If the injection is not given deep enough into a muscle, the solution may penetrate the fatty tissue, possibly resulting in inflammation, hardening and destruction (necrosis) of the tissue. ● It is been reported that following leaking of the solution from a vein into the surrounding tissue calcium deposition in the soft tissue may occur. It may be followed by peeling and destruction of the skin . ● Redness of the skin and a feeling of burn or pain during intravenous injection may indicate an inadvertent injection beside the blood vessel, which could result in the destruction of the tissue.
Reporting of side effects If you get any side effects talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
5.
Calcium Gluconate 10 % w/v Injection BP
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the container and carton. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. The solution must be used immediately once the ampoule has been opened. After diluting the ready-to-use solution must be administered as soon as possible but should not be stored for longer than 24 hours at 2 – 8° C. Do not use this medicine if you notice the following changes: ● damage to the ampoule, discolouration or cloudiness (turbidity) of the solution, visible particles in the solution. Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
Content of the pack and other information
What Calcium Gluconate 10 % w/v Injection BP contains
● ●
The active substance is calcium gluconate. 1 ml of solution contains 94 mg of calcium gluconate, equivalent to 0.21 mmol calcium 10 ml contains 940 mg of calcium gluconate, equivalent to 2.10 mmol calcium
●
Excipients: The product also contains an amount of the excipient calcium D-saccharate tetrahydrate equivalent to 0.02 mmol calcium per ml (or 0.15 mmol calcium per 10ml).
●
The other ingredient is water for injections.
Total calcium content: 0.23 mmol per ml (2.25 mmol per 10ml). What Calcium Gluconate 10 % w/v Injection BP looks like and contents of the pack Calcium Gluconate 10 % w/v Injection BP is a solution for injection (a solution that is administered in a syringe). It is a clear, colourless to light brown aqueous solution. It comes in: Polyethylene ampoules, content: 10 ml available in packs of 20 x 10 ml Marketing Authorisation Holder and Manufacturer: B. Braun Melsungen AG Carl-Braun-Straße 1 34212 Melsungen Germany Postal address: 34209 Melsungen Germany Phone: +49-5661-71-0 Fax: +49-5661-71-4567
This leaflet was last revised in 01/2024 ———————————————————————————————————————————-The following information is intended for healthcare professionals only:
Method of administration In the case of adipose patients a longer needle will have to be chosen for safe positioning of the injection into the muscle and not into the adipose tissues. If repeated injections are necessary, the injection site should be changed every time.
Paediatric patients (< 18 years) Only slow intravenous injection or intravenous infusion (both after dilution), in order to achieve sufficiently low administration rates and to avoid irritation/necrosis in case of accidental extravasation. The intravenous administration rate should not exceed 5 ml of a 1:10 dilution per minute of Calcium Gluconate 10% w/v Injection BP in children and adolescents.
Special warnings and precautions for use In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calciumcontaining intravenous solutions even via different infusion lines or different infusion sites. Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term newborns aged less than 1 month have been described. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. Sequential infusions of ceftriaxone and calcium-containing products must be avoided in case of hypovolaemia. Risk of medications errors due to non-equivalence of calcium gluconate and calcium chloride salts Calcium gluconate and calcium chloride are presented in 10 ml ampoules at 10% (w/v) for injection but are not equivalent in calcium content:
Dilution For intravenous infusion, Calcium Gluconate 10% w/v Injection BP may be diluted 1:10 to a concentration of 10 mg/ml with the following two infusion fluids: sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection. When diluted with these recommended infusion fluids, the resulting solutions are intended for immediate single use. Dilution should be performed under controlled and validated aseptic conditions. After mixing, the container should be gently agitated to ensure homogeneity.
Treatment of overdose Initial management should include rehydration and, in severe hypercalcaemia, it may be necessary to administer isotonic sodium chloride solution by intravenous infusion to expand the extracellular fluid. Calcitonin may be given to lower the elevated serum calcium concentration. Furosemide may be administered to increase calcium excretion but thiazide diuretics should be avoided as they may increase renal absorption of calcium. Serum electrolytes should be carefully monitored throughout treatment of overdose.
Calcium Gluconate 10% w/v Injection BP comes as injection. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Calcium Gluconate 10% w/v Injection BP is calcium gluconate.
Medicines with the same active substance, strength and form include: Calcium Gluconate 10% solution for injection/infusion BP. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Calcium Gluconate 10% w/v Injection BP, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Treatment of acute symptomatic hypocalcaemia.
- Treatment of acute severe hyperkalaemia with or without ECG changes, as an emergency treatment aiming to reduce cardiac cell excitability (cardioprotective effect) while other measures to lower potassium levels are instituted.
- Cardiac arrest only due to severe hyperkalaemia.
The normal concentration of calcium in plasma is within the range of 2.25 – 2.62 mmol per litre. Treatment should be aimed at restoring this level. During therapy, serum calcium levels should be monitored closely.
Posology
Treatment of acute symptomatic hypocalcaemia
Adults
The usual initial dose in adults is 10 ml of Calcium Gluconate 10 % w/v Injection BP, corresponding to 2.25 mmol of calcium.
If necessary, the dose may be repeated, depending on the patient's clinical condition. Subsequent doses should be adjusted according to the actual serum calcium level.
Paediatric patients (< 18 years):
The dose and the route of administration depend on the degree of hypocalcaemia and the nature and severity of the symptoms. In the case of mild neuromuscular symptoms oral calcium administration should be preferred.
The following table gives usual initial dosage values for guidance:
Age
ml/kg
3 months
0.4 – 0.9
6 months
0.3 – 0.7
1 year
0.2 – 0.5
3 years
0.4 – 0.7
7.5 years
0.2 – 0.4
12 years
0.1 – 0.3
> 12 years
as for adults
In cases of severe symptoms of hypocalcaemia in neonates or infants, e.g. cardiac symptoms, higher initial doses (up to 2 ml per kg body weight, ≙ 0.45 mmol calcium per kg body weight) may be necessary for a quick restoration of a normal serum calcium level.
Also, if necessary, the dose may be repeated, depending on the patient's clinical condition. Subsequent doses should be adjusted according to the actual serum calcium level.
Intravenous therapy should be followed by oral administration if indicated, e.g. in cases of calciferol deficiency.
Treatment of acute severe hyperkalaemia with or without ECG changes
Adults
Acute severe hyperkalaemia with or without ECG changes (serum potassium concentration above 6.5 mmol/L).
30 ml of Calcium Gluconate 10 % w/v Injection BP (corresponding to 6.69 mmol calcium) administered undiluted as a slow intravenous injection over 10 minutes.
Further doses can be considered after 5 minutes, if needed, until ECG improvement is achieved.
Paediatric population
The dose regimen for cardiac arrest should be followed.
Treatment of cardiac arrest due to hyperkalaemia
Treatment should be tailored to the individual patient. The onset of action of intravenous calcium gluconate is within three minutes. With a relatively short duration of action (30 – 60 minutes) further doses may be necessary if hyperkalaemia remains uncontrolled.
Adults
30 ml of Calcium Gluconate 10 % w/v Injection BP (corresponding to 6.69 mmol calcium) administered undiluted as a rapid intravenous injection.
Further doses can be repeated if return of spontaneous circulation is not achieved within 5-10 minutes, or if the resuscitation attempt is prolonged.
Paediatric population
Neonates (0 to 27 days)
0.5 ml/kg body weight of Calcium Gluconate 10 % w/v Injection BP (corresponding to 0.11 mmol calcium/kg body weight) administered undiluted (in the case of emergency) as a slow intravenous injection over 5-10 minutes.
The dose should be given centrally whenever possible. If no central access is available, the dose should be diluted with sodium chloride 0.9% to five times the volume.
The dose can be repeated if ECG changes persist after 5-10 minutes following administration of the first dose.
Children (28 days to < 18 years)
0.5 ml/kg of body weight of Calcium Gluconate 10 % w/v Injection BP (corresponding to 0.11 mmol calcium/kg body weight) by slow intravenous injection over 5-10 minutes.
In the case of emergency, Calcium gluconate 10 % w/v Injection BP can be administered undiluted via central IV access.
The dose can be diluted to 50 ml with sodium chloride 0.9% over 10 minutes.
The dose can be repeated if ECG changes persist after 5-10 minutes following administration of the first dose.
In children with a body weight ≥ 20 kg a maximum recommended dose of 20 ml of Calcium Gluconate 10 % w/v Injection BP (corresponding to 4.46 mmol calcium) can be given.
Elderly patients
Although there is no evidence that tolerance of calcium gluconate injection is directly affected by advanced age, factors that may sometimes be associated with ageing, such as impaired renal function and poor diet, may indirectly affect tolerance and may require a reduction in dosage.
Method of administration
The patient should be in the lying position and should be closely observed during injection. Monitoring should include heart rate or ECG.
Adults
Intravenous use or intramuscular use. Because of the risk of local irritation, deep intramuscular injections should only be performed if slow intravenous injection is not possible.
Care should be taken to administer the intramuscular injections sufficiently deep intramuscular, preferably into the gluteal region (see sections 4.4 and 4.8).
In the case of adipose patients a longer needle will have to be chosen for safe positioning of the injection into the muscle and not into adipose tissues.
If repeated injections are necessary, the injection site should be changed every time.
According to the NHS guideline for the treatment of hypocalcaemia in adults the intravenous administration rate should not exceed 2 ml (0,45 mmol of calcium) per minute.
Paediatric patients (< 18 years)
Only slow intravenous injection or intravenous infusion (both after dilution), in order to achieve sufficiently low administration rates and to avoid irritation/necrosis in case of accidental extravasation.
The intravenous administration rate should not exceed 5 ml of a 1:10 dilution per minute (see section 6.6) of Calcium Gluconate 10% B. Braun in children and adolescents.
Intramuscular injections should not be performed in paediatric patients.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Hypercalcaemia (e.g. in patients with hyperparathyroidism, hypervitaminosis D, decalcifying malignancies, renal insufficiency, immobilisation osteoporosis, sarcoidosis, milk-alkali syndrome)
- Hypercalciuria
- Intoxication with cardiac glycosides
- Therapy with cardiac glycosides.
The only exception may be that intravenous calcium administration is imperative for treatment of severe hypocalcaemia symptoms or acute severe hyperkalaemia putting the patient at immediate vital risk, if safer therapeutic alternatives are not available and calcium administration via the oral route is not possible (see sections 4.4 and 4.5).
- Concomitant use of ceftriaxone and intravenous calcium-containing products is contraindicated in premature neonates and neonates (≤ 28 days of age). Ceftriaxone should not be used in premature neonates and neonates (≤ 28 days of age) if they are receiving (or are expected to receive) calcium-containing intravenous products.
Special warnings
In the exceptional case of intravenous administration of calcium gluconate to patients receiving cardiac glycosides, adequate cardiac monitoring is mandatory and emergency treatment of cardiac complications such as serious arrhythmias must be available (see also sections 4.2, 4.3 and 4.5). Calcium Gluconate 10% solution for injection/infusion should be administered slowly (in 100 ml glucose 5% over 20 minutes). Rapid calcium administration may precipitate myocardial digoxin toxicity therefore other methods e.g. haemodialysis should also be considered after consultation with specialists.
Calcium salts should only be used with caution and after careful establishment of the indication in patients with nephrocalcinosis, heart diseases, sarcoidosis (Boeck's disease), in patients receiving epinephrine (see section 4.5), or in the elderly.
Renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism. Therefore, in patients with renal impairment, parenteral calcium should be administered only after careful assessment of the indication and the calcium-phosphate balance should be monitored.
Calcium gluconate and calcium chloride are presented in 10 ml ampoules at 10% (w/v) for injection but are not equivalent in calcium content:
- 10 ml of Calcium Gluconate 10 % w/v Injection BP contains 2.23 mmol calcium
- 10 ml of calcium chloride 10% solution contains 6.8 mmol of calcium
The difference in calcium content should be accounted for to achieve the correct calcium dose when using either salt to avoid medication errors.
Patients receiving ceftriaxone
In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solutions even via different infusion lines or different infusion sites (see section 6.2).
Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term newborns aged less than 1 month have been described.
However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation.
Sequential infusions of ceftriaxone and calcium-containing products must be avoided in case of hypovolaemia.
Calcium Gluconate 10% solution for injection/infusion must not be mixed with or administered through the same intravenous line as sodium bicarbonate (sometimes used for treatment of severe hyperkalaemia) due to the risk of precipitation.
Precautions for use
Solutions containing calcium should be administered slowly to minimise peripheral vasodilation and cardiac depression.
Intravenous injections should be accompanied by heart rate or ECG control because bradycardia with vasodilatation or arrhythmia can occur when calcium is administered too quickly.
In paediatic patients, Calcium Gluconate 10 % w/v Injection BP should not be injected intramuscularly but only slowly intravenously.
Patients receiving calcium salts should be monitored carefully to ensure maintenance of correct calcium balance without tissue deposition.
Plasma levels and urinary excretion of calcium should be monitored when high-dose parenteral calcium is administered.
Calcium Gluconate 10 % w/v Injection BP should not be injected in adipose tissue as calcium is insoluble in adipose tissue and may cause infiltration and subsequent abscess formation, tissue indurations and necrosis.
After perivascular or superficial intramuscular injection local irritation, possibly followed by skin ablation or tissue necrosis, may occur (see section 4.8). Extravasation must be avoided; the injection site should be monitored carefully.
High Vitamin D intake should be avoided.
Cardiac glycosides
The effects of digoxin and other cardiac glycosides may be potentiated by calcium, which may result in serious toxicity. Therefore, intravenous administration of calcium preparations to patients under therapy with cardiac glycosides is contraindicated. The only exception may be that intravenous calcium administration is imperative for treatment of severe hypocalcaemia symptoms or acute severe hyperkalaemia putting the patient at immediate vital risk, if safer therapeutic alternatives are not available and calcium administration via the oral route is not possible (see sections 4.3 and 4.4).
Epinephrine
Co-administration of calcium and epinephrine attenuate epinephrine's β-adrenergic effects in postoperative heart surgery patients (see section 4.4).
Magnesium
Calcium and magnesium mutually antagonise their effects.
Calcium antagonists
Calcium may antagonise the effect of calcium antagonists (calcium channel blockers).
Thiazide diuretics
Combination with thiazide diuretics may induce hypercalcaemia as these medicinal products reduce renal calcium excretion.
Physical incompatibilities including interaction with ceftriaxone and sodium bicarbonate
See sections 4.4 and 6.2.
Pregnancy
Calcium passes across the placental barrier and its concentration in foetal blood is higher than in maternal blood.
Calcium Gluconate 10%w/v Injection BP should not be used during pregnancy unless the clinical condition of the woman requires treatment with Calcium Gluconate 10%w/v Injection BP. The administered dose should be carefully calculated, and the serum calcium level regularly evaluated in order to avoid hypercalcaemia, which may be deleterious for the foetus.
Breast-feeding
Calcium is excreted in breast milk. This should be borne in mind when administering calcium to women who are breast-feeding their infants. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Calcium Gluconate 10%w/v Injection BP therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
No data available.
Not relevant.
The frequency of undesirable effects listed below is defined using the following convention:
Very common
Common
Uncommon
Rare
Very rare
Not known
≥1/10
≥1/100 to <1/10
≥1/1,000 to <1/100
≥1/10,000 to <1/1,000
<1/10,000
Frequency cannot be estimated from the available data.
Cardiovascular and other systemic undesirable effects are likely to occur as symptoms of acute hypercalcaemia resulting from intravenous overdose or too rapid intravenous injection. Their occurrence and frequency is directly related to the administration rate and the administered dose.
Cardiac disorders
Not known:
Bradycardia, cardiac arrhythmia
Vascular disorders
Not known:
Hypotension, vasodilatation, circulatory collapse (possibly fatal), flushing, mainly after too rapid injection
Gastrointestinal disorders
Not known:
Nausea, vomiting
General disorders and administration site conditions
Not known:
Heat sensations, sweating
Not known:
Intramuscular injection may be accompanied by pain sensations or erythema.
Ceftriaxone-calcium salt precipitation
Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 6.2).
Adverse reactions only occurring with improper administration technique:
If intramuscular injection is not performed sufficiently deep intramuscularly, infiltration into the adipose tissue may occur with subsequent abscess formation, tissue induration, and necrosis.
Calcinosis cutis, possibly followed by skin ablation and necrosis, due to extravasation, has been reported.
Reddening of skin, burning sensation or pain during intravenous injection may indicate accidental perivascular injection, which may lead to tissue necrosis.
Reporting of suspected adverse reactions
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms
Symptoms of hypercalcaemia may include: anorexia, nausea, vomiting, constipation, abdominal pain, polyuria, polydipsia, dehydration, muscle weakness, bone pain, renal calcification, drowsiness, confusion, hypertension and, in severe cases, cardiac arrhythmia up to cardiac arrest, and coma.
If intravenous injection is too rapid, symptoms of hypercalcaemia may occur as well as a chalky taste, hot flushes and hypotension.
Emergency treatment, antidotes
Treatment should be aimed at lowering the elevated plasma calcium concentration.
Initial management should include rehydration and, in severe hypercalcaemia, it may be necessary to administer sodium chloride by intravenous infusion to expand the extracellular fluid. Calcitonin may be given to lower the elevated serum calcium concentration. Furosemide may be administered to increase calcium excretion but thiazide diuretics should be avoided as they may increase renal absorption of calcium.
Haemodialysis or peritoneal dialysis may be considered where other measures have failed and where the patient remains acutely symptomatic. Serum electrolytes should be carefully monitored throughout treatment of overdose.
Ask anything about Calcium Gluconate 10% w/v Injection BP. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.